Anelise Poluboiarinov Cappellaro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anelise Poluboiarinov Cappellaro has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Samuel Menezes
Departamento de Ciências da Saúde, Universidade Federal da Bahia, Salvador, Brazil
3 shared publications - Luiz Felipe Costa de Almeida
Department of Medical Sciences, Federal Fluminense University , Rio de Janeiro
2 shared publications - Luís Felipe Leite
Department of Medical Sciences, Universidade Federal Fluminense, RJ, Brazil
2 shared publications - Marcos Belotto
Hospital 9 de Julho, Brazil
2 shared publications - Mariana Macambira Noronha
Department of Medical Sciences, Universidade Federal do Ceará, CE, Brazil
2 shared publications - Renata Peixoto
Department of Medical Oncology, BC Cancer Agency, Vancouver, Canada
2 shared publications
Latest Publications
- Open Access
- 9 February 2026
- Published by Wiley in Journal of Hepato-Biliary-Pancreatic Sciences
- Vol. 33 (5) , 333-342
Critical Appraisal of Pancreaticogastrostomy After Pancreatoduodenectomy: Evolution, Evidence, and Future Prospects
Pancreaticogastrostomy (PG) emerged as a reconstructive option after pancreaticoduodenectomy (PD) due to its reported lower incidence of postoperative pancreatic fistula (POPF), but its superiority over pancreaticojejunostomy (PJ) remains unclear. We provide a narrative review that summarizes its evolution, technical variations, and comparative outcomes versus PJ. A narrative review from a comprehensive literature search was conducted using electronic databases of Medline/PubMed, EMBASE, and the Cochrane Library to identify relevant studies addressing surgical techniques, outcomes, and comparative analyses. PG offers anatomical, physiological advantages, including tension‐free anastomosis and gastric acid inactivation of pancreatic enzymes. Early RCTs showed similar clinically relevant POPF rates. Later trials supported PG for soft glands and small ducts, showing fewer intraperitoneal collections but more hemorrhage. Despite similar short‐term outcomes, long‐term randomized follow‐up shows worse exocrine function after PG than PJ, with higher fecal fat, lower fecal elastase‐1, and greater pancreatic atrophy. PG is an effective reconstruction option after PD, particularly in POPF high‐risk cases. However, it has higher bleeding rates and worse long‐term exocrine function than PJ. Reconstruction should prioritize pancreatic function, favoring PJ for most patients and reserving PG for selected soft, small‐duct, or high‐risk glands based on institutional expertise.
- 9 February 2026
- Published by Wiley in Journal of Hepato-Biliary-Pancreatic Sciences
- Vol. 33 (5) , 333-342
Open AccessCritical Appraisal of Pancreaticogastrostomy After Pancreatoduodenectomy: Evolution, Evidence, and Future Prospects
Pancreaticogastrostomy (PG) emerged as a reconstructive option after pancreaticoduodenectomy (PD) due to its reported lower incidence of postoperative pancreatic fistula (POPF), but its superiority over pancreaticojejunostomy (PJ) remains unclear. We provide a narrative review that summarizes its evolution, technical variations, and comparative outcomes versus PJ. A narrative review from a comprehensive literature search was conducted using electronic databases of Medline/PubMed, EMBASE, and the Cochrane Library to identify relevant studies addressing surgical techniques, outcomes, and comparative analyses. PG offers anatomical, physiological advantages, including tension‐free anastomosis and gastric acid inactivation of pancreatic enzymes. Early RCTs showed similar clinically relevant POPF rates. Later trials supported PG for soft glands and small ducts, showing fewer intraperitoneal collections but more hemorrhage. Despite similar short‐term outcomes, long‐term randomized follow‐up shows worse exocrine function after PG than PJ, with higher fecal fat, lower fecal elastase‐1, and greater pancreatic atrophy. PG is an effective reconstruction option after PD, particularly in POPF high‐risk cases. However, it has higher bleeding rates and worse long‐term exocrine function than PJ. Reconstruction should prioritize pancreatic function, favoring PJ for most patients and reserving PG for selected soft, small‐duct, or high‐risk glands based on institutional expertise.
- 11 November 2025
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 61 (2) , 162783
One-stage versus two-stage ERCP followed by laparoscopic cholecystectomy for the management of pediatric choledocholithiasis: A systematic review and meta-analysis
- 11 November 2025
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 61 (2) , 162783
One-stage versus two-stage ERCP followed by laparoscopic cholecystectomy for the management of pediatric choledocholithiasis: A systematic review and meta-analysis
- Open Access
Anti-EGFR Therapy in Metastatic Colorectal Cancer: Identifying, Tracking, and Overcoming Resistance
Epidermal growth factor receptor (EGFR) inhibitors remain a cornerstone in the treatment of metastatic colorectal cancer with RAS and BRAF wild-type cancer. Yet, primary and acquired resistance limit their benefit for many patients. A growing body of evidence reveals that resistance is not random but rather driven by a complex network of molecular alterations that sustain tumor growth independent of EGFR signaling. These include amplification of ERBB2 (HER2) and MET, activation of the PI3K and AKT pathways, EGFR extracellular domain mutations, and rare kinase fusions. The concept of negative hyperselection has emerged as a powerful strategy to refine patient selection by excluding tumors with these resistance drivers. Multiple clinical trials have consistently shown that patients who are hyperselected based on comprehensive molecular profiling achieve significantly higher response rates and improved survival compared to those selected by RAS and BRAF status alone. Liquid biopsy through circulating tumor DNA has further transformed this landscape, offering a noninvasive tool to capture tumor heterogeneity, monitor clonal evolution in real time, and guide rechallenge strategies after resistance emerges. Together, negative hyperselection, ctDNA-guided monitoring, and emerging therapeutics define a precision-oncology framework for identifying, tracking, and overcoming resistance to anti-EGFR therapy in mCRC, moving the field toward more effective and individualized care. Looking ahead, the development of innovative therapeutics such as bispecific antibodies, antibody drug conjugates, and RNA-based therapies promises to further expand in this challenging clinical scenario. These advances move precision oncology in colorectal cancer from concept to clinical reality, reshaping the standard of care through molecular insights.
Open AccessAnti-EGFR Therapy in Metastatic Colorectal Cancer: Identifying, Tracking, and Overcoming Resistance
Epidermal growth factor receptor (EGFR) inhibitors remain a cornerstone in the treatment of metastatic colorectal cancer with RAS and BRAF wild-type cancer. Yet, primary and acquired resistance limit their benefit for many patients. A growing body of evidence reveals that resistance is not random but rather driven by a complex network of molecular alterations that sustain tumor growth independent of EGFR signaling. These include amplification of ERBB2 (HER2) and MET, activation of the PI3K and AKT pathways, EGFR extracellular domain mutations, and rare kinase fusions. The concept of negative hyperselection has emerged as a powerful strategy to refine patient selection by excluding tumors with these resistance drivers. Multiple clinical trials have consistently shown that patients who are hyperselected based on comprehensive molecular profiling achieve significantly higher response rates and improved survival compared to those selected by RAS and BRAF status alone. Liquid biopsy through circulating tumor DNA has further transformed this landscape, offering a noninvasive tool to capture tumor heterogeneity, monitor clonal evolution in real time, and guide rechallenge strategies after resistance emerges. Together, negative hyperselection, ctDNA-guided monitoring, and emerging therapeutics define a precision-oncology framework for identifying, tracking, and overcoming resistance to anti-EGFR therapy in mCRC, moving the field toward more effective and individualized care. Looking ahead, the development of innovative therapeutics such as bispecific antibodies, antibody drug conjugates, and RNA-based therapies promises to further expand in this challenging clinical scenario. These advances move precision oncology in colorectal cancer from concept to clinical reality, reshaping the standard of care through molecular insights.
- 25 April 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 222, 115476
Neoadjuvant chemotherapy for colon cancer: A systematic review and meta-analysis of randomized controlled trials
- 25 April 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 222, 115476
Neoadjuvant chemotherapy for colon cancer: A systematic review and meta-analysis of randomized controlled trials